Alterity Therapeutics Limited (ATHE) Income Statement
ATHE FY2026 at a glance
Fiscal year ended June 30, 2026 · Australian dollarsATHE revenue and net income
ATHE profit margins
ATHE growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −102.1% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATHE income statement in Australian dollars
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$0 | A$5.4M | A$4.0M | A$3.9M | A$5.1M | A$4.3M | A$411,567 | A$108,538 | A$201,174 | A$132,396 |
| Cost of revenue | A$113,010 | A$127,523 | A$214,304 | A$285,067 | A$364,665 | A$360,026 | A$112,427 | A$29,696 | A$21,799 | A$21,328 |
| Gross profit | −A$113,010 | A$5.3M | A$3.8M | A$3.6M | A$4.8M | A$4.0M | −A$112,427 | A$78,842 | A$179,375 | A$111,068 |
| Research & development | A$17.2M | A$14.4M | A$18.6M | A$13.2M | A$14.7M | A$12.3M | A$10.1M | A$13.0M | A$6.7M | A$5.7M |
| Sales, general & admin | A$10.4M | A$5.5M | A$4.8M | A$5.0M | A$5.5M | A$6.9M | A$3.3M | A$4.3M | A$4.4M | A$3.9M |
| Total operating expenses | A$27.7M | A$19.9M | A$23.4M | A$18.2M | A$20.3M | A$19.2M | A$10.1M | A$12.5M | A$11.1M | A$6.8M |
| Operating income | −A$27.8M | −A$14.6M | −A$19.6M | −A$14.6M | −A$15.5M | −A$15.2M | −A$10.4M | −A$12.7M | −A$7.8M | −A$6.9M |
| Interest income | A$1.7M | A$446,291 | A$268,419 | A$16,436 | A$2,504 | A$20,676 | A$17,117 | A$108,538 | A$201,174 | A$132,396 |
| Interest expense | — | — | — | — | A$2,504 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Income before taxes | −A$26.3M | −A$12.1M | −A$19.1M | −A$13.7M | −A$12.8M | −A$15.3M | −A$10.1M | −A$12.3M | −A$8.3M | −A$7.5M |
| Income taxes | −A$3.4M | A$68,055 | A$46,088 | A$104,459 | A$70,008 | −A$3.1M | −A$362,188 | −A$376,031 | −A$495,440 | A$660,213 |
| Net income | −A$22.9M | −A$12.1M | −A$19.1M | −A$13.8M | −A$12.8M | −A$15.3M | −A$10.1M | −A$12.0M | −A$8.3M | −A$7.5M |
| EBITDA | −A$27.7M | −A$14.5M | −A$19.5M | −A$14.5M | −A$17.4M | −A$15.1M | −A$13.3M | −A$12.8M | −A$11.4M | −A$6.9M |
| Gross margin | — | 97.7% | 94.7% | 92.7% | 92.9% | 91.7% | −27.3% | 72.6% | 89.2% | 83.9% |
| Operating margin | — | −268.0% | −487.7% | −373.7% | −302.6% | −349.8% | −2,530.3% | −11,713.7% | −3,862.5% | −5,197.9% |
| Net margin | — | −223.4% | −475.8% | −352.5% | −250.7% | −352.8% | −2,444.2% | −11,020.8% | −4,108.8% | −5,696.6% |
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$0 | A$0 | A$3.8M | A$1.6M | A$802,963 | A$2.1M | A$1.1M | A$1.9M | A$950,362 | A$1.5M | A$765,247 | A$2.4M |
| Cost of revenue | A$58,457 | A$56,828 | A$63,924 | A$63,598 | A$31,799 | A$73,612 | A$58,668 | A$73,917 | A$48,484 | A$52,267 | A$62,517 | A$49,996 |
| Gross profit | −A$58,457 | −A$56,828 | A$3.8M | A$1.5M | A$771,164 | A$2.0M | A$1.0M | A$1.8M | A$901,878 | A$1.5M | A$702,730 | A$2.3M |
| Research & development | A$9.9M | A$7.7M | A$8.7M | A$5.7M | A$2.9M | A$12.3M | A$6.1M | A$6.4M | A$3.2M | A$5.4M | A$2.7M | A$7.8M |
| Sales, general & admin | — | — | A$2.5M | A$3.3M | A$1.7M | A$2.7M | A$1.4M | A$2.1M | A$1.0M | A$2.3M | A$1.1M | A$2.9M |
| Total operating expenses | A$15.5M | A$12.8M | A$10.9M | A$9.0M | A$4.5M | A$15.0M | A$7.5M | A$8.4M | A$4.2M | A$7.7M | A$3.8M | A$10.7M |
| Operating income | −A$15.6M | −A$12.8M | −A$7.1M | −A$7.5M | −A$3.7M | −A$13.0M | −A$6.5M | −A$4.5M | −A$3.3M | −A$7.8M | −A$3.1M | −A$10.7M |
| Income before taxes | −A$14.7M | −A$12.1M | −A$4.9M | −A$8.8M | −A$3.6M | −A$14.7M | −A$6.3M | −A$4.4M | −A$3.3M | −A$7.3M | −A$2.9M | −A$10.3M |
| Income taxes | −A$765,306 | −A$2.7M | A$68,055 | −A$1.6M | — | −A$2.1M | A$23,044 | −A$1.9M | — | −A$1.5M | A$280 | −A$2.3M |
| Net income | −A$14.0M | −A$9.4M | −A$5.0M | −A$7.2M | −A$3.6M | −A$12.6M | −A$6.3M | −A$6.5M | −A$3.3M | −A$5.8M | −A$2.9M | −A$8.0M |
| EBITDA | −A$15.5M | −A$12.8M | −A$7.0M | −A$7.5M | −A$3.8M | −A$14.6M | −A$6.5M | −A$8.3M | −A$3.3M | −A$7.2M | −A$3.1M | −A$10.3M |
| Gross margin | — | — | 98.3% | 96.0% | 96.0% | 96.5% | 94.5% | 96.1% | 94.9% | 96.6% | 91.8% | 97.9% |
| Operating margin | — | — | −184.9% | −466.2% | −466.2% | −612.8% | −612.8% | −236.8% | −348.2% | −507.9% | −407.9% | −450.6% |
| Net margin | — | — | −129.8% | −446.7% | −446.7% | −595.5% | −595.5% | −342.4% | −342.4% | −377.3% | −377.3% | −336.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported in ATHE's financial statements (latest annual report filed August 28, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATHE financial results
Alterity Therapeutics reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of A$22.9 million. Figures are in Australian dollars, the currency of its financial statements.
See the ATHE stock overview for the latest quote and news, or the ATHE chart for price history and technical indicators.
ATHE income statement FAQ
Does Alterity Therapeutics have revenue?
Alterity Therapeutics reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is Alterity Therapeutics profitable?
No. Alterity Therapeutics reported a net loss of A$22.9 million in fiscal 2026.
How much does Alterity Therapeutics spend on research and development?
Alterity Therapeutics spent A$17.2 million on research and development in fiscal 2026.
When does Alterity Therapeutics's fiscal year end?
Alterity Therapeutics's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 28, 2026.